Sirolimus rescue of renal failure in children after combined liver-kidney transplantation.
BACKGROUND
Calcineurin inhibitors (CNI) are the main immunosuppressive drugs in solid organ transplantation. However, their use is hampered by side effects like nephrotoxicity. We report an exceptional experience with three children treated with sirolimus after combined liver and kidney transplantation with prolonged renal failure and CNI-associated nephrotoxicity.


RESULTS
Two girls experienced prolonged renal graft failure after combined liver-kidney transplantation for 11 and 12 weeks. Repeated biopsies did not show any rejection but did exhibit tubular damage and acute CNI-toxicity. A boy with hyperoxaluria after liver and (a third) renal transplantation experienced acute renal graft failure after an early steroid-resistant rejection. All children were switched to sirolimus-based immunosuppression and cessation of CNI therapy, which was followed by rapid improvement of renal function. Rejection of liver or kidney did not occur after CNI withdrawal. Sirolimus was commenced with 3 mg/m2/day in two doses and resulted in reasonable drug exposure. However, drug monitoring was required to adjust sirolimus dosage.


CONCLUSIONS
Prolonged renal failure after transplantation with severe CNI toxicity may be salvaged successfully with sirolimus-based immunosuppression.
Vester
Udo
U
Clinic of Pediatric Nephrology, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany. udo.vester@medizin.uni-essen.de
Kranz
Birgitta
B
Nadalin
Silvio
S
Paul
Andreas
A
Becker
Jan
J
Hoyer
Peter F
PF
D000208:Acute Disease; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008297:Male; D016879:Salvage Therapy; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus
Nephrol Dial Transplant. 1990;5(5):332-6
2115623
J Am Soc Nephrol. 2004 Jan;15(1):228-33
14694177
Pediatr Transplant. 2001 Jun;5(3):215-31
11422826
Am J Transplant. 2004 Jan;4(1):130-1
14678044
Kidney Int. 1998 Sep;54(3):972-8
9734625
Pediatrics. 1976 Aug;58(2):259-63
951142
Cell. 1992 Jun 26;69(7):1227-36
1377606
Semin Nephrol. 2003 Sep;23(5):465-76
13680536
Transplant Proc. 2003 Jun;35(4):1292-4
12826140
J Am Soc Nephrol. 2001 May;12(5):1059-71
11316866
J Am Soc Nephrol. 2004 Mar;15(3):809-17
14978184
Lancet. 2000 Jan 29;355(9201):376-7
10665560
Pediatr Transplant. 2004 Apr;8(2):171-7
15049798
Pediatr Transplant. 2004 Aug;8(4):362-6
15265163
Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8
11583941
Lancet. 2000 Jul 15;356(9225):194-202
10963197
Transplantation. 2002 Oct 27;74(8):1070-6
12438948
Transplantation. 2001 Sep 15;72(5):851-5
11571449
Am J Transplant. 2004 May;4(5):767-73
15084173
Am J Physiol Renal Physiol. 2001 Oct;281(4):F693-706
11553517